SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organisation expert consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Public Health. Lancet 2004; 363: 15763.
  • 2
    Wang J, Thornton JC, Russell M, Burastero S, Heymsfield SB, Pierson RN. Asians have lower body mass index (BMI) but higher percent body fat than do whites: comparisons of anthropometric measurements. American Journal of Clinical Nutrition 1994; 60: 238.
  • 3
    Rosenbaum M, Leibel RL, Hirsch J. Obesity. New England Journal of Medicine 1997; 337: 396407.
  • 4
    International Obesity Task Force secretariat. The Global Challenge of Obesity and the International Obesity Task Force October 2002 (WWW document). http://www.iuns.org/features/obesity/obesity.htm.
  • 5
    Bosello O, Zamboni M. Visceral obesity and metabolic syndrome. Obesity Reviews 2000; 1: 4756.
  • 6
    Zamboni M, Armellini F, Sheiban I, et al. Relation of body fat distribution in men and degree of coronary narrowings in coronary artery disease. American Journal of Cardiology 1992; 70: 11358.
  • 7
    Adams JP, Murphy PG. Obesity in anaesthesia and intensive care. British Journal of Anaesthesia 2000; 85: 91108.
  • 8
    Mokhdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. Journal of the American Medical Association 2004; 291: 123845.
  • 9
    Cameron AJ, Welborn TA, Zimmet PZ, et al. Overweight and obesity in Australia. The 1999–2000 Australian diabetes, obesity and lifestyle study (AustDiab). Medical Journal of Australia 2003; 178: 42732.
  • 10
    Troiano RP, Flegal KM. Overweight children and adolescents: Description, epidemiology, and demographics. Pediatrics 1998; 101: 497504.
  • 11
    Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term morbidity and mortality of overweight adolescents: a follow-up of the Harvard Growth Study of 1922–35. New England Journal of Medicine 1992; 327: 13505.
  • 12
    Druce M, Bloom SR. Central regulators of food intake. Current Opinion in Clinical Nutrition and Metabolic Care 2003; 6: 3617.
  • 13
    Frankish HM, Dryden S, Hopkins D, Wang Q, Williams G. Neuropeptide Y, the hypothalamus, and diabetes: insights into the central control of metabolism. Peptides 1995; 16: 75771.
  • 14
    Bagnol D, Lu XY, Kaelin CB, et al. Anatomy of an endogenous antagonist: relationship between Agouti-related protein and proopiomelanocortin in brain. Journal of Neuroscience 1999: 19: RC26.
  • 15
    Olszewski PK, Wickwire K, Wirth MM, Levine AS, Giraudo SQ. Agouti-related protein: appetite or reward? Annals of the New York Academy of Sciences 2003; 994: 18791.
  • 16
    Shutter JR, Graham M, Kinsey AC, Scully S, Luthy R, Stark KL. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes and Development 1997; 11: 593602.
  • 17
    Boutin JA, Suply T, Audinot V, et al. Melanin-concentrating hormone and its receptors: state of the art. Canadian Journal of Physiology and Pharmacology 2002; 80: 38895.
  • 18
    Preti A. Orexins (hypocretins): their role in appetite and arousal. Review. Current Opinion in Investigational Drugs 2002; 3: 1199206.
  • 19
    Leibowitz SF. Brain peptides and obesity: Pharmacologic treatment. Obesity Research 1995; 3: S57389.
  • 20
    Reizes O, Lincecum J, Wang Z, et al. Transgenic expression of syndecan-1 uncovers a physiological control of feeding behavior by syndecan-3. Cell 2001; 106: 10516.
  • 21
    Snitker S, Macdonald I, Ravussin E, Astrup A. The sympathetic system and obesity: role in aetiology and treatment. Obesity Reviews 2000; 1: 515.
  • 22
    Zimanyi IA, Pelleymounter MA. The role of melanocortin peptides and receptors in regulation of energy balance. Current Pharmaceutical Design 2003; 9: 62741.
  • 23
    Nagle DL, McGrail SH, Vitale J, et al. The mahogany protein is a receptor involved in the suppression of obesity. Nature 1999; 398: 14852.
  • 24
    Matteri RL. Overview of central targets for appetite regulation. Journal of Animal Science 2001; 79: E14858.
  • 25
    Drazen DL, Woods SC. Peripheral signals in the control of satiety and hunger. Current Opinion in Clinical Nutrition and Metabolic Care 2003; 6: 6219.
  • 26
    Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New England Journal of Medicine 1996; 334: 2925.
  • 27
    Matson CA, Wiater MF, Kuijper JL, Weigle DS. Synergy between leptin and cholecystokinin (CCK) to control daily caloric intake. Peptides 1997; 18: 12758.
  • 28
    Ghizzoni L, Mastorakos G. Interactions of leptin, GH, and cortisol in normal children. Annals of the New York Academy of Sciences 2003; 997: 5663.
  • 29
    Woods SC, Chavez M, Park CR, et al. The evaluation of insulin as a metabolic signal influencing behavior via the brain. Neuroscience and Biobehavioral Reviews 1996; 20: 13944.
  • 30
    Air EL, Benoit SC, Clegg DJ, et al. Insulin and leptin combine additively to reduce food intake and body weight in rats. Endocrinology 2002; 143: 244952.
  • 31
    Drucker DJ. Glucagon-like peptides. Diabetes 1998; 47: 15969.
  • 32
    Batterham RL, Bloom SR. The gut hormone peptide YY regulates appetite. Annals of the New York Academy of Sciences 2003; 994: 1628.
  • 33
    Batterham RL, Cohen MA, Ellis SM, et al. Original articles: inhibition of food intake in obese subjects by Peptide YY (3–36). New England Journal of Medicine 2003; 349: 9418.
  • 34
    Naslund E, Gryback P, Hellstrom PM, et al. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. International Journal of Obesity and Related Metabolic Disorders 1997; 21: 38792.
  • 35
    Cummings DE, Shannon MH. Roles for ghrelin in the regulation of appetite and body weight. Archives of Surgery 2003; 138: 38996.
  • 36
    Cummings DE, Weigle DS, Frayo RS, et al. Human plasma ghrelin levels after diet-induced weight loss and gastric bypass surgery. New England Journal of Medicine 2002; 346: 162330.
  • 37
    Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends in Endocrinology and Metabolism 2000; 11: 32732.
  • 38
    Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumour necrosis factor-alpha in human obesity and insulin resistance. Journal of Clinical Investigation 1995; 95: 240915.
  • 39
    Chandran M, Phillips S, Cairaldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 244250.
  • 40
    Beltowski J. Adiponectin and resistin – new hormones of white adipose tissue. Medical Science Monitor 2003: 9: RA5561.
  • 41
    Bergstrom RW, Newell-Morris LL, Leonetti DL, Shuman WP, Wahl PW, Fujimoto WY. Association of elevated fasting C-peptide level and increased intra-abdominal fat distribution with development of NIDDM in Japanese-American men. Diabetes 1990; 39: 10411.
  • 42
    Després JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. British Medical Journal 2001; 322: 71620.
  • 43
    Schiffelers SLH, Saris WHM, Van Baak MA. Beta 1- and beta 2-adrenergic receptor stimulation of thermogenesis and lipid utilization in obese and lean men. British Journal of Clinical Pharmacology 1999; 47: 46970.
  • 44
    Grujic D, Susulic VS, Harper ME, et al. Beta 3-adrenergic receptors on white and brown adipocytes mediate beta 3-selective agonist-induced effects on energy expenditure, insulin secretion and food intake. Journal of Biological Chemistry 1997; 272: 1768693.
  • 45
    Van Baak MA. The peripheral sympathetic nervous system in human obesity. Obesity Reviews 2001; 2: 314.
  • 46
    Pi-Sunyer FX, Laferrere B, Aronne LJ, Bray GA. Therapeutic controversy: Obesity – A modern-day epidemic. Journal of Clinical Endocrinology and Metabolism 1999; 84: 312.
  • 47
    Cousin B, Munoz O, Andre M, et al. A role for preadipocytes as macrophage-like cells. FASEB 1999; 14: 30512.
  • 48
    Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. FASEB Jorunal 1998; 12: 5765.
  • 49
    Correia ML, Haynes WG. Leptin, obesity and cardiovascular disease. Current Opinion of Nephrology and Hypertension 2004; 13: 21523.
  • 50
    Marti A, Marcos A, Martinez A. Obesity and immune function relationships. Obesity Reviews 2001; 2: 13140.
  • 51
    Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obesity Reviews 2002; 3: 85101.
  • 52
    Primrose JN, Davies JA, Prentice CRM, Hughes R, Johnston D. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thrombosis and Haemostasis 1992; 68: 3969.
  • 53
    Birgel M, Gottschling-Zeller H, Röhrig K, Hauner H. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arteriosclerosis, Thrombosis and Vascular Biology 2000; 20: 16827.
  • 54
    Wolf C, Tanner M. Obesity. Western Journal of Medicine 2002; 176: 238.
  • 55
    Howard BV, Ruotolo G, Robbins DC. Obesity and dyslipidemia. Endocrinology and Metabolic Clinics of North America 2003; 32: 85567.
  • 56
    Persson AV, Davis RJ, Villavicencio JL. Deep venous thrombosis and pulmonary embolism. Surgical Clinics of North America 1991; 71: 1195209.
  • 57
    Herrera MF, Oseguera J, Gamino R, et al. Cardiac abnormalities associated with morbid obesity. World Journal of Surgery 1998; 22: 9937.
  • 58
    Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. New England Journal of Medicine 2002; 347: 30513.
  • 59
    Koenig SM. Pulmonary complications of obesity. American Journal of the Medical Sciences 2001; 321: 24979.
  • 60
    Young T, Palta M, Dempsey J, Skatrud J, Webber S, Bader S. The occurrence of sleep-disordered breathing among middle-aged adults. New England Journal of Medicine 1993; 328: 12305.
  • 61
    Barak N, Ehrenpreis ED, Harrison JR, Sitrin MD. Gastro-oesophageal reflux disease in obesity: pathophysiological and therapeutic considerations. Obesity Reviews 2002; 3: 915.
  • 62
    Grodstein F, Goldman MB, Cramer DW. Body mass index and ovulatory infertility. Epidemiology 1994; 5: 24750.
  • 63
    Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obesity Reviews 2003; 4: 15773.
  • 64
    Pi-Sunyer FX. Comorbidities of overweight and obesity; current evidence and research issues. Medicine and Science in Sports and Exercise 1999; 31: S6028.
  • 65
    Goldstein DJ. Beneficial health effects of modest weight loss. International Journal of Obesity 1992; 16: 397415.
  • 66
    Kiess W, Galler A, Reich A, et al. Clinical aspects of obesity in childhood and adolescence. Obesity Reviews 2001; 2: 2936.
  • 67
    Lyznicki JM, Young DC, Riggs JA, Davis RM. Obesity: assessment and management in primary care. American Family Physician 2001; 63: 218596.
  • 68
    Noel PH, Pugh JA. Management of overweight and obese adults. British Medical Journal 2002; 325: 75761.
  • 69
    Vermunt SHF, Pasman WJ, Schaafsma G, Kardinaal AFM. Effects of sugar intake on body weight: a review. Obesity Reviews 2003; 4: 919.
  • 70
    Garrow JS, Summerbell CD. Meta-analysis: effect of exercise, with or without dieting, on the body composition of overweight subjects. European Journal of Clinical Nutrition 1995; 49: 110.
  • 71
    Katzmarzyk PT, Janssen I, Ardern CI. Physical inactivity, excess adiposity and premature mortality. Obesity Reviews 2003; 4: 25790.
  • 72
    Miller WC, Jacob AV. The health at any size paradigm for obesity treatment: the scientific evidence. Obesity Reviews 2001; 2: 3745.
  • 73
    Yanovski SZ, Yanovski JA. Drug therapy: obesity. New England Journal of Medicine 2002; 346: 591602.
  • 74
    National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. Journal of the American Medical Association 1996; 276: 190715.
  • 75
    Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obesity Reviews 2000; 1: 12739.
  • 76
    Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998; 21: 128894.
  • 77
    Allison DB, Fontaine KR, Heshka S, Mentore JL, Heymsfield SB. Alternative treatments for weight loss: a critical review. Critical Reviews in Food Science and Nutrition 2001; 41: 128.
  • 78
    Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care 1996; 19: 9206.
  • 79
    Ettinger MP, Litlejohn TW, Schwartz SL, et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose ranging study. Preliminary communication. Journal of the American Medical Association 2003; 289: 182632.
  • 80
    Vastag B. Experimental drugs take aim at obesity. Journal of the American Medical Association 2003; 289: 17634.
  • 81
    Ishihara A, Kanatani A, Okada M, et al. Blockade of weight gain and plasma cortisone levels in Zucker fatty rats using an orally active neuropeptide Y Y1 antagonist. British Journal of Pharmacology 2002; 136: 3416.
  • 82
    McMinn JE, Wilkinson CW, Havel PJ, Woods SC, Schwartz MW. Effect of intracerebroventricular alpha-MSH on food intake, adiposity, c-Fos induction, and neuropeptide expression. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2000; 279: R695703.
  • 83
    Kral J. Surgical treatment of obesity. In: Bjorntrop, P, ed. International Textbook of Obesity. Sussex: John Wiley, 2001: 5118.
  • 84
    Benotti PN, Armour Forse R. The role of gastric surgery in the multidisciplinary management of severe obesity. American Journal of Surgery 1995; 169: 3616.
  • 85
    Gentileschi P, Kini S, Catarci M, Gagner M. Evidence-based medicine: open and laparoscopic bariatric surgery. Surgical Endoscopy 2002; 16: 73644.
  • 86
    Fobi MAL, Lee H, Holness R, Cabinda D. Gastric bypass operation for obesity. World Journal of Surgery 1998; 22: 92535.
  • 87
    Wudel LJ Jr, Wright JK, Debelak JP, et al. Prevention of gall-stone formation in morbidly obese patients undergoing rapid weight loss: results of a randomized controlled pilot study. Journal of Surgical Research 2002; 102: 506.
  • 88
    Ovrebo KK, Hatlebakk JG, Viste A, Bassoe HH, Svanes K. Gastroesophageal reflux in morbidly obese patients treated with gastric banding or vertical banded gastroplasty. Annals of Surgery 1998; 228: 518.
  • 89
    Belachew M, Legrand M, Vincent V, Lismonde M, Le Docte N, Deschamps V. Laparoscopic adjustable gastric banding. World Journal of Surgery 1998; 22: 95563.
  • 90
    Deitel M. Overview of operations for morbid obesity. World Journal of Surgery 1998; 22: 9138.
  • 91
    Livingston EH. Obesity and its surgical management. American Journal of Surgery 2002; 184: 10313.
  • 92
    Cummings DE, Shannon MH. Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss? Journal of Clinical Endocrinology and Metabolism 2003; 88: 29993002.
  • 93
    Herron DM. The surgical management of severe obesity. Mount Sinai Journal of Medicine 2004; 71: 6371.
  • 94
    Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Annals of Surgery 2003; 237: 7518.
  • 95
    Cowan GSM, Buffington CK. Significant changes in blood pressure, glucose, and lipids with gastric bypass surgery. World Journal of Surgery 1998; 22: 98792.
  • 96
    Higa KD, Boone KB, Ho T, Davies OG. Laparoscopic Roux-en-Y gastric bypass for morbid obesity: technique and preliminary results of our first 400 patients. Archives of Surgery 2000; 135: 102934.
  • 97
    Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Annals of Surgery 2000; 232: 51529.
  • 98
    Perugini RA, Mason RMS, Czerniach DR, et al. Predictors of complication and suboptimal weight loss after laparoscopic Roux-en-Y gastric bypass: a series of 188 patients. Archives of Surgery 2003; 138: 5416.
  • 99
    Podnos YD, Jimenez JC, Wilson SE, Stevens CM, Nguyen NT. Complications after laparoscopic gastric bypass. A review of 3464 cases. Archives of Surgery 2003; 138: 95761.
  • 100
    Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion. World Journal of Surgery 1998; 22: 93646.